Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin added to GLP-1 analogue in type 2 diabetes
NCT02227849Phase 4Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Aug 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Adverse Events at 52 weeks. Started Aug 2014; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02227849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227849.